By Mackenzie Tatananni
Shares of Insmed surged by double digits after the global biopharmaceutical company unveiled positive results for an experimental drug trial.
Shares soared 26% to $89.32 in early trading, putting them on track for their highest close since June 29, 2001, according to Dow Jones Market Data. The S&P 500 and Nasdaq Composite were each up about 0.1%.
Insmed is working on a treatment called treprostinil palmitil inhalation powder taken once daily by patients with pulmonary arterial hypertension, a progressive disease affecting the lungs and heart.
In the latest Phase 2b study, patients saw a statistically significant 35% reduction relative to a placebo in pulmonary vascular resistance, or the amount of pushback blood encounters as it travels through the lungs to the heart.
The biopharma company pledged to immediately engage with the U.S. Food and Drug Administration regarding the design for future studies.
Insmed said it intends to launch a Phase 3 trial for patients with pulmonary hypertension associated with interstitial lung disease before the end of 2025. It plans a Phase 3 trial for patients with PAH in early 2026.
Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
June 10, 2025 09:52 ET (13:52 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。